Assessment (GRA), Interstitial Cystitis Symptom/Problem Index (ICSIPI) and Overactive Bladder symptom severity (OABq ss)/health related quality of life (HRQOL) collected at baseline, 3 and 6 months, and 1 and 2 years were analyzed with descriptive statistics and repeated measures over 1 year.
INTRODUCTION AND OBJECTIVES: Refractory urgency urinary incontinence (UUI) can be treated with onabotulinumtoxinA and sacral neuromodulation but it is unclear whether treatment response differs based on patient characteristics. The objective was to identify clinical and demographic factors associated with treatment response in women participating in a randomized trial comparing efficacy of these two therapies.
METHODS: These data were obtained from the Refractory Overactive Bladder: Sacral Neuromodulation vs Botulinum Toxin Assessment (ROSETTA) trial. Adjusting for clinical site, age stratum and treatment, univariable analyses were performed to identify baseline participant characteristics and clinical variables associated with each treatment using two definitions of response: 1) a reduction of mean daily UUIE longitudinally over 6 months 2) 50% decrease in UUIE across 6 months. Variables with p0.1 were included in multivariable analyses. Linear and logistic regression models were fit to estimate each outcome and reported as mean reductions and adjusted odds ratios (OR) with 95% confidence intervals (CI), respectively. RESULTS: Variables significantly associated with treatment response on univariable and multivariable analyses are noted in the table. Increasing age, higher BMI and higher baseline IIQ score significantly reduced the chances of achieving 50% decrease in UUIEs at 6 months for both treatments with a significantly greater effect noted with age in the onabotulinumtoxinA group. A mean reduction in daily UUIE over 6 months was independently associated with higher baseline HUI scores and greater baseline UUIE per day. Higher health utility index scores also had a greater effect on participants in the onabotulinumtoxinA group. Increasing age was associated with less reduction in UUIE per day.
CONCLUSIONS: Six months after treatment, age, BMI, baseline UUIE, IIQ and HUI were similarly associated with treatment response in women undergoing sacral neuromodulation and onabotu-linumtoxinA with interesting differential effects noted with age and HUI. This information may assist in counseling patients regarding the efficacy and expectations of these treatment modalities for women with refractory UUI. METHODS: This is a prospective, randomized, blind study. Adult female patients, with symptoms of OAB, who had failed conservative treatment or discontinued pharmacotherapy due to intolerability or contraindications were included. Patients who had any neurological disease, tumors, pelvic abnormalities or voiding dysfunction were excluded. Detrusor overactivity was not required for inclusion. They Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1047
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were assessed at 4,12 and 24 weeks after injection. Treatment consisted of 30 injections distribuited into the detrusor muscle, avoiding trigone. The primary outcome was change in clinical status, including urinary frequency, urgency and urinary urgency incontinence (UUI) episodes. Secondary outcomes were changes in maximum cystometric capacity (MCC), volume at first desire to void (FDV) and post-void residual (PVR). Quality of life (QoL) was assessed using a visual analogue scale (VAS,0-10) and a patient global impression of improvement (PGI-I).Urinary retention, urinary tract infection (UTI) and required clean intermitent catheterization (CIC) were adverse events. RESULTS: A total of 22 patients were randomized to either 300U (n¼11) or 500U (n¼11) groups. Baseline demographics characteristics were comparable for both groups. All 21 patients reported urgency, with 90% of UUI before treatment. At 12 w, an important reduction in daily UUI episodes was observed in two groups, with 90% of them being dry. Decrease in mean episodes of nocturia and urinary frequency, increase FDV and CCM and a mean reduction in total ICIQ-OAB were observed. At 24 w, episodes of UUI had returned in 50% (300U) and 0% (500U) (p¼0,013). Patients had an impression of significant improvement in 70% (300U) and 88,9% (500U) at 12w; and 50% (300U) and 100% (500U),at 24w. Score of VAS was manteined higher in 500U group. There was a significant increase in mean PVR after treatment (4w) in both groups. Our incidence of UTI was 36,7% (300U) and 34,6% (500U). One patient (500U) required CIC for 2 weeks.
CONCLUSIONS: Data from this study suggest 500U improves symptoms and quality of life for longer time than 300U. However, results are not significantly differents to determine which dose is safer. As far we know this is the first study to compare two doses of Abobotuli-numtoxinA for refractory idiophatic OAB.
Source of Funding: none

PD54-07 EXPRESSION OF MIR221 AND MIR125B IN BLADDER BIOPSY PREDICT THE RISK OF HIGH PVR FOLLOWING INTRADETRUSOR ONABOTULINUMTOXIN-A INJECTION: IMPLICATIONS FOR CLINICAL DECISION MAKING
Christopher J Chermansky*, Brian T Kadow, Mahendra Kashyap, Pradeep Tyagi, Pittsburgh, PA INTRODUCTION AND OBJECTIVES: Micro RNAs (miRs) are non-coding strands of RNA involved in gene expression. Because of their relative stability in urine and serum, miRs are widely researched as promising biomarkers that may better help understand chronic diseases. The role of miRs in the pathology and treatment outcomes of onabotulinumtoxin-A (onaBoNT-A) in overactive bladder (OAB) patients is unknown. Here, we identified the miRs associated with elevated postvoid residual volumes (PVRs) >200ml following intradetrusor injection of onaBoNT-A 100IU.
METHODS: 14 female OAB patients with urgency urinary incontinence refractory to OAB drugs were consented for this study. Cystoscopic-guided punch bladder biopsy was obtained at the time of injecting 100 units of onaBoNT-A. RNA was extracted from the biopsy for measuring the expression of 13 miR species using TaqMan Universal PCR Master Mix in quantitative PCR. The miR species were selected for their known effect on neurotrophin expression and smooth muscle function. Relative expression for each miR was determined after normalizing to U6 small nuclear RNA. PVRs and urine Nerve Growth Factor (NGF) levels were measured at baseline and at the follow-up visit 3 weeks later.
RESULTS: Consented 14 patients had a mean age of 66 years (Range 46-80 years). Of these patients, 9 maintained PVRs < 200mL (0-120 mL) after injection of onaBoNT-A to comprise the low PVR group. The other 5 patients developed PVRs > 200mL (213-391mL), and they comprise the high PVR group. The mean pre-procedure PVR was similar in both groups. Relative expression of miR221 and miR125b (see Figure 1 ) was upregulated by 11 and 2 fold, respectively (*p<0.05, Mann-Whitney U test) in patients who maintained low PVRs after onaBoNT-A. The expression of other 11 miR species and urine NGF levels at baseline were not significantly different between the two groups. Even though the NGF levels were similar in two groups but the 11 fold downregulation of miR221 may attenuate the action of NGF in high PVR group.
CONCLUSIONS: This study suggests that deficiency in the pretreatment expression of miR221 and miR125b may predispose OAB patients to high PVRs following intradetrusor onaBoNT-A. Additional studies are needed to understand the role of each miR in OAB pathology and treatment outcomes. INTRODUCTION AND OBJECTIVES: Intravesical onabotulinum toxin A (Botoxâ) is an effective treatment for idiopathic detrusor overactivity of which urinary tract infections (UTIs) are a common complication. We previously identified a UTI rate of 35.1% in patients who received a single intramuscular (IM) dose of a third-generation cephalosporin (ceftriaxone) at the time of Botox injection. Given this high rate of infection despite single-dose antibiotic prophylaxis, we changed our practice pattern to determine if a longer course of antibiotic treatment would decrease the UTI rate following intravesical Botox injection.
METHODS: We retrospectively evaluated patients undergoing intravesical Botox injections from May 2012 to November 2016. All procedures were performed at the same office location. One group of patients, with negative pre-procedure urine cultures, was given an IM dose of a third-generation cephalosporin. A second group, also with negative pre-procedure cultures, received a 3-day course of an oral fluoroquinolone starting the day before Botox injection. Data abstracted included age, BMI, history of diabetes, pre/post procedure urine culture. Pre-procedure UTI was defined as asymptomatic bacteriuria. The postprocedure UTI rate was examined using a c 2 test. A secondary analysis was performed using logistic regression modeling to test the association between clinical characteristics and antibiotic regimen and risk of postprocedure UTI.
RESULTS: 284 Botox injections were performed over the study period -236 patients received a single IM dose of ceftriaxone and 48 patients received three days of oral ciprofloxacin. There was no difference in the baseline age, BMI, diabetes, or rate of pre-procedure positive culture between the two groups. Overall, the UTI rate was significantly lower in the fluoroquinolone group (20.8%) vs. the e1048 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 
